 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || anti-BCMA CAR-T cells / Hrain Biotech
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM (clinicaltrials.gov) - Jan 3, 2025
P1, N=18, Active, not recruiting, Sponsor: Hrain Biotechnology Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||| anti-BCMA CAR-T cells / Hrain Biotech
New P2 trial: Human BCMA Targeted T Cells Injection?BCMA CAR-T?for Subjects With R/R MM (clinicaltrials.gov) - Oct 26, 2022
P2, N=100, Recruiting, Sponsor: Hrain Biotechnology Co., Ltd.
- || anti-BCMA CAR-T cells / Hrain Biotech
New P1 trial, IO biomarker: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM (clinicaltrials.gov) - Mar 31, 2022
P1, N=18, Recruiting, Sponsor: Hrain Biotechnology Co., Ltd.
- || lenalidomide / Generic mfg.
Clinical, Journal: Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. (Pubmed Central) - Jan 18, 2022
We demonstrated for the first time in patients that anti-BCMA CAR-T cell therapy combined with lenalidomide is feasible and effective in the treatment of RRMM. It provides a new strategy for RRMM patients who do not respond to anti-BCMA CAR-T cell therapy alone, and the adverse event is reversible.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, CAR T-Cell Therapy: A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. (Pubmed Central) - Sep 12, 2021
It provides a new strategy for RRMM patients who do not respond to anti-BCMA CAR-T cell therapy alone, and the adverse event is reversible. We confirm that BCMA is a suitable target for CAR- T cells and tEGFR is a effective tool for cellular ablation.
- || anti-BCMA CAR-T cells / Hrain Biotech
Enrollment open: BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 31, 2021
P1, N=10, Recruiting, Sponsor: Hrain Biotechnology Co., Ltd.
We confirm that BCMA is a suitable target for CAR- T cells and tEGFR is a effective tool for cellular ablation. Not yet recruiting --> Recruiting
- | anti-BCMA CAR-T cells / Hrain Biotech
New P1 trial: BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2019
P1, N=10, Not yet recruiting, Sponsor: Hrain Biotechnology Co., Ltd.
- | anti-BCMA CAR-T cells / Hrain Biotech
New P1 trial: BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma (clinicaltrials.gov) - Mar 28, 2017
P1, N=10, Recruiting, Sponsor: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine